Digital BIOCoV

Early prediction of anti-COVID-19 activity on biomolecules present in fungi and microalgae through the application of Machine Learning techniques integrating biological and chemical data

Digital BIOCoV is a project for the early prediction of anti-COVID-19 activity on biomolecules present in fungi and microalgae through the application of Machine Learning techniques integrating biological and chemical data (IN852D 2021/11).

Companies: Hifas da Terra, AMSbiopharma, CIFGA and Plexus Technologies.

Objective: The overall aim of the project is to accelerate development by applying prediction-based techniques to chemical and biological data for the discovery of new anti-COVID-19 treatments from fungal and microalgae extracts.

The consortium that will carry out this project is made up of one large Galician company and three Galician SMEs: Hifas da Terra (project leader), AMSbiopharma, CIFGA and Plexus, with support from the University of Santiago de Compostela as a subcontracted collaborating entity, who will each jointly participate in the running of the project.

This way, DIGITAL-BIOCoV will make use of digital R&D technologies during the discovery phase of bioactive fractions or molecules that may be effective against SARS-CoV-2, incorporating bioactivity and chemical data to explore their patentability, value or originality for the pharmaceutical market.

This project is subsidised by the Galician Innovation Agency (GAIN), financed by the ERDF and has the support of the Xunta de Galicia (Regional Government of Galicia) through the second vice-presidency and the Regional Ministry of Economy, Enterprise and Innovation. The operation is funded by the CONECTA COVID 2021 programme in the framework of the REACT-EU initiative run by the ERDF Galicia 2014-2020 programme as part of the European Union‘s response to the COVID-19 pandemic.

Total budget: €314,486.93